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Acute Heart Failure Syndromes
Mihai Gheorghiade, MD, FACC,* Peter S. Pang, MD†
Chicago, Illinois
Heart failure resulting in hospitalization represents a significant and growing health care burden. Heterogeneity
characterizes this group in terms of mode of presentation, pathophysiology, and prognosis. The vast majority of
patients symptomatically improve during hospitalization; however, their early post-discharge rehospitalization
and mortality rates continue to be high. Worsening signs and symptoms, neurohormonal, and renal abnormali-
ties occurring soon after discharge may contribute to these high post-discharge event rates. Currently available
assessment modalities combined with recent advances in cardiovascular therapies provide present-day opportu-
nities to improve post-discharge outcomes. Further investigation into pathophysiologic targets and novel ap-
proaches to clinical trial design are needed. Improving post-discharge outcomes is the single most important
goal in the management of acute heart failure syndromes. (J Am Coll Cardiol 2009;53:557–73) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.041d
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Oospitalization for acute heart failure syndromes (AHFS) is 1
f the most important predictors of post-discharge mortality
nd readmission in patients with chronic HF (1,2). Over 1
illion hospitalizations with a primary diagnosis of HF occur
ach year in the U.S. (3). As a diagnosis at hospital discharge,
F has tripled over the last 3 decades. This trend will likely
ontinue due to an aging population, improved survival after
yocardial infarction (MI), and better prevention of sudden
ardiac death (3,4).
Management of AHFS is challenging given the heter-
geneity of the patient population, absence of a univer-
ally accepted definition, incomplete understanding of
ts pathophysiology, and lack of robust evidence-based
uidelines. The majority of patients appear to respond
ell to initial therapies consisting of loop diuretics and
asoactive agents (5–7). However, post-discharge mor-
ality and rehospitalization rates reach 10% to 20% and
0% to 30%, respectively, within 3 to 6 months (6,8).
lthough this may reflect the severity of HF, myocardial
njury and/or renal impairment occurring in AHFS may
ontribute to this grim prognosis. Improving post-
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ccepted October 26, 2008.ischarge mortality and prevention of readmissions are
he most important goals in AHFS.
This review reflects concepts developed by the Inter-
ational Working Group on AHFS that met annually for
he last 5 years, composed of cardiologists, hospitalists,
mergency physicians, industry, and governmental agen-
ies (5).
efinitions
HFS can be defined as new onset or gradual or rapidly
orsening HF signs and symptoms requiring urgent therapy
5). Irrespective of the underlying cause (e.g., ischemic
vent) or precipitant (e.g., severe hypertension), pulmonary
nd systemic congestion due to elevated ventricular filling
ressures with or without a decrease in cardiac output is a
early universal finding in AHFS (5). Coronary artery disease
CAD), hypertension, valvular heart disease, and/or atrial
brillation, as well as noncardiac conditions such as renal
ysfunction, diabetes, anemia, and medications (i.e., nonste-
oidal anti-inflammatory drugs, glitazones), may also contrib-
te to these abnormalities (5,9–11). The majority of AHFS
atients have worsening chronic HF; after initial management
esulting in stabilization, they should no longer be considered
cute but chronic HF (11).
atient Characteristics
eart failure afflicts over 5 million Americans and 15 million
uropeans (3,11–13). The cost in the U.S. is over 34 billion
ollars per year, mainly related to hospitalizations, with similar
nancial burdens for many European countries (3,11–13).
ver 1 million hospital discharges for HF occurred in 2005 inhe U.S., an increase of 171% compared with discharges in
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lion hospital diagnoses of HF oc-
curred in 2004 (3). Between 1992
and 2001, there were 10.5 million
U.S. emergency department visits
for AHFS, with an average in-
crease of 18,500 visits each year
(4). AHFS resulting in hospital-
ization is the most common
diagnosis-related group for Medi-
care patients and in total, the most
expensive (3,12–14). Only re-
cently, AHFS registries from
Europe and the U.S. provided us
with an accurate characterization
and prognosis of these patients
(6,7,9,10,15–20). However, less
is known from other geographi-
cal regions.
Patient characteristics. The ma-
jority of AHFS patients have
worsening chronic HF resulting in
hospitalization, with the remain-
ing 15% to 20% diagnosed with
HF for the first time. The mean
age is 75 years and over one-half
are women. Dyspnea and signs of
congestion manifested by jugular
venous distention and edema are
common (9,15,21). At presenta-
ion, approximately 25% of patients are hypertensive (systolic
lood pressure [SBP] 160 mm Hg), 10% are hypotensive,
ost are taking diuretics, 40% take angiotensin-converting
nzyme (ACE) inhibitors, 10% take angiotensin-receptor
lockers, 50% take beta-blockers, and 20% to 30% take digoxin
9,18,21). A history of CAD is present in 60%, hypertension in
0%, diabetes in 40%, atrial fibrillation in 30%, and moderate
o severe renal impairment in 20% to 30% (22).
Approximately 50% of AHFS patients have a relatively
reserved systolic function (PSF) (6,7,9,15,23). They are
lder and more likely to be female. They are also more likely
o have a history of hypertension and atrial arrhythmias, and
resent with severe hypertension (6,7,23) (Table 1).
recipitants for admission. Hospitalization commonly re-
ults from congestion or fluid overload and not a low cardiac
utput (9,24). Congestion, due to an increase in left ventricular
lling pressure (LVFP) (hemodynamic congestion) often re-
ults in jugular venous distention, peripheral edema, and/or an
ncrease in body weight (BW) (clinical congestion). This often
tarts days if not weeks before admission (25,26). Hospitaliza-
ion for HF, in itself, is 1 of the most important predictors for
ehospitalization (1,2). Both in the U.S. and Europe, uncon-
rolled hypertension, ischemia, arrhythmias, exacerbation of
hronic obstructive pulmonary disease with or without pneu-
onia, and noncompliance (dietary and/or medication) are
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AHFS  acute heart failure
syndromes
ARB  angiotensin
receptor blocker
BNP  B-type natriuretic
peptide
BP  blood pressure
BW  body weight
CAD  coronary artery
disease
CRT  chronic
resynchronization therapy
EF  ejection fraction
HF  heart failure
IV  intravenous
LVFP  left ventricular
filling pressure
MI  myocardial infarction
PCWP  pulmonary
capillary wedge pressure
PSF  preserved systolic
function
SBP  systolic blood
pressureajor precipitants for admission (27). In patients presenting sith de novo HF, a significant number are diagnosed with
cute coronary syndrome (19).
linical course. Most patients have rapid symptomatic
mprovement with loop diuretics and have a relatively short
ospital stay (4,9,15,18). Although systemic and pulmonary
ongestion is the main reason for hospitalization, many do
ot have a decrease in BW during hospitalization and are
ften discharged with HF signs and/or symptoms (7,28,29).
ften a comprehensive assessment is not performed (e.g.,
ardiac catheterization, assessment for viable, but dysfunc-
ional myocardium). This may result in underutilization of
vidence-based therapies (5,28,30,31). In patients admitted
ith worsening chronic HF, except for diuretic dose esca-
ation, introduction of new or up-titration of evidence-based
herapies (e.g., ACE inhibitors, beta-blockers) is 5% to
0%. In fact, they are often discharged on the same
re-admission medications (8,15,32).
The mean length of stay in the U.S. is 6 days (median:
days) (9,18). In-hospital mortality (2% to 4%) may reach
0% for those patients with severe renal impairment and
ow SBP. However, this group represents 2% to 5% of
he overall AHFS population (6). Post-discharge mortal-
ty varies at 60 to 90 days from 5% to 15% depending on
P at presentation (the higher the BP, the lower the
ortality). The readmission rate is approximately 30%,
ndependent of SBP at presentation (21). Risk for these
vents is highest in the first few months following
ischarge (2,31). Recent data suggests an association
etween early events and worsening symptoms, renal
unction, and neurohormonal profile during the first few
eeks after discharge (33). Among patients admitted
ith chronic HF and low ejection fraction (EF), approx-
mately 40% will die from progressive HF and 30% will
ie suddenly and unexpectedly post-discharge (31). Ap-
roximately 50% of readmissions are not related to HF.
arly post-discharge events in PSF patients appear sim-
lar to those with reduced EF, although the mode of
eath and reason for rehospitalization has not been
tudied in these patients (6). It is possible that a signif-
cant number of morbid events in the AHFS/PSF pop-
lation are related to coexisting cardiac or noncardiac
omorbidities, such as CAD, hypertension, atrial fibril-
ation, renal insufficiency, or stroke (34,35).
linical Classification
atients may be classified into HF presenting for the first time
de novo) or worsening chronic HF (5) (Fig. 1). In both
roups, the presence and extent of CAD may determine the
nitial, in-hospital, and post-discharge management (36). The
F may influence post-discharge rather than initial manage-
ent, which should be based on the presenting clinical profile.
f the approximately 80% of AHFS patients with chronic HF
esulting in hospitalization, 5% to 10% have advanced HF.
ow blood pressure, renal impairment, and/or signs andymptoms refractory to standard therapy characterize
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Table 1 Preserved Versus Reduced Systolic Function Patient Characteristics
Characteristics at Admission
Patients With LVSD
(n  20,118)
Patients With PSF
(n  21,149)
Demographics
Age, yrs 70.4  14.3 75.1  13.1
Male 62% 38%
Caucasian 71% 77%
African American 21% 15%
Medical history
Diabetes, insulin-treated 15% 17%
Diabetes, noninsulin-treated 24% 26%
Hypertension 66% 76%
Hyperlipidemia 34% 32%
Atrial arrhythmia 28% 33%
Vital signs on admission
Body weight, kg 78.5 [65.8, 94.0] 78.9 [64.0, 97.5]
Heart rate, beats/min 89  22 85  21
SBP, mm Hg 135  31 149  33
DBP, mm Hg 77  19 76  19
Etiology
Ischemic 54% 38%
Hypertensive 17% 28%
Idiopathic 18% 21%
Findings on admission
Acute pulmonary edema 3% 2%
Chest pain 23% 24%
Uncontrolled hypertension 9% 12%
Dyspnea at rest 44% 44%
Dyspnea on exertion 63% 62%
Rales 63% 65%
Lower extremity edema 62% 68%
Jugular venous distention 33% 26%
Left ventricular EF, % 24.3  7.7 54.7  10.2
Laboratory values
Serum sodium, mEq/l 137.7  4.6 137.9  4.8
Serum creatinine, mg/dl 1.4 [1.1, 1.9] 1.3 [1.0, 1.8]
Serum hemoglobin, g/dl 12.5  2.0 11.9  2.0
BNP, pg/ml 1,170.0 [603.0, 2,280.0] 601.5 [320.0, 1,190.0]
Troponin I, ng/ml 0.1 [0.1, 0.3] 0.1 [0.0, 0.3]
Medications on admission
ACE inhibitor 45% 36%
ARB 11% 13%
Amlodipine 5% 10%
Aldosterone antagonist 10% 5%
Beta-blocker 56% 52%
Loop diuretic 63% 58%
Digoxin 30% 17%
Aspirin 42% 38%
Antiarrhythmic 13% 8%
Hydralazine 3% 3%
Nitrate 22% 21%
Statin* 40% 39%
Data presented as percent, mean  SD, or median [25th, 75th percentiles]. Adapted and reproduced, with permission, from Fonarow et al.
(6). *Statin use among patients with coronary artery disease, cerebrovascular disease/transient ischemic attack, diabetes, hyperlipidemia, or
peripheral vascular disease.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BNP  B-type natriuretic peptide; DBP  diastolic blood pressure;
EF  ejection fraction; LVSD  left ventricular systolic dysfunction; PSF  preserved systolic function; SBP  systolic blood pressure.
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Acute HF Syndromes February 17, 2009:557–73dvanced HF. De novo HF represents the remainder of
HFS and may be further divided into those with
re-existing risk for HF (e.g., hypertension, CAD) with-
ut evidence of prior LV dysfunction or structural abnor-
alities and those with pre-existing cardiac structural
bnormalities (e.g., reduced EF) (13).
athophysiology
HFS are characterized by severe hemodynamic and neu-
ohormonal abnormalities that may cause myocardial injury
nd/or renal dysfunction or may be a result of it (11,37,38).
hese abnormalities may be caused or precipitated by
schemia, hypertension, atrial fibrillation, other noncardiac
onditions (e.g., renal insufficiency), or untoward drug
ffects (11,39–42).
ongestion. High LV diastolic pressure resulting in pul-
onary and systemic congestion with or without low
ardiac output is the main reason for presentation in the
ajority of patients (5,9,24,37,43,44). Pulmonary conges-
ion may be defined as pulmonary venous hypertension
increased pulmonary capillary wedge pressure [PCWP])
ften resulting in pulmonary interstitial and alveolar edema.
ystemic congestion manifests clinically by jugular venous
istention with or without peripheral edema and gradual
ncreases in BW are often seen (11) (Table 2). Occasionally,
evere pulmonary congestion develops abruptly when pre-
ipitated by a rapid increase in BP (afterload), particularly in
atients with diastolic dysfunction (45–48). Renal impair-
ent, severe neurohormonal or endothelial abnormalities,
ietary indiscretion, and certain medications such as non-
teroidal anti-inflammatory drugs, glitazones, and first gen-
ration calcium-channel blockers, may also contribute to
De novo HF
Chronic HF
Worsening
*
Figure 1 General Clinical Classification
Broad general classification proposed for AHFS patients representing key factors t
of chronic HF. †With or without acute coronary syndromes. Figure illustration by Rouid overload (5,27,49–52).
N
pHigh LV diastolic pressure, by itself, may contribute to
he progression of HF by further causing activation of
eurohormones, subendocardial ischemia, and/or changes
n LV size and shape (remodeling) that often results in
itral insufficiency (24,53–55). Increased systemic venous
ressure (high right atrial pressure), most commonly caused
Preserved EF
Reduced EF
y influence management. *Advanced HF is a subset
ell. CAD  coronary artery disease; EF  ejection fraction; HF  heart failure.
ssessment of Congestion
Table 2 Assessment of Congestion
BW Increase in BW predicts hospitalization (26,33). However, a
reduction in BW in response to different therapies may not
necessarily result in decreased hospitalization or mortality.
Heart rate and
rhythm
Both bradyarrhythmias and tachyarrhythmias can contribute to
congestion.
BP Either no change in BP or an increase in BP from supine to the
upright position or during Valsalva maneuver usually reflects
a relatively high LV filling pressure (113).
Jugular venous
pressure
Equals RA pressure. In a chronic state, the RA pressure
correlates with PCWP/LVDP.
Rales Associated with increase in PCWP when present with other
signs of elevated filling pressure (e.g., JVD, S3), but is
nonspecific by itself.
Edema Peripheral edema, only when associated with JVD, indicates
right-sided failure that is usually associated with left-sided
HF. During hospitalization, may move from dependent
periphery to the sacral area.
Orthopnea test Patients often do not tolerate lying flat when there is a rapid
increase in filling pressure. However, in a chronic state, this
position may be tolerated in spite of a relatively high filling
pressure.
BNP/NT-proBNP Marker of increased LV filling pressures.
Chest X-ray Pulmonary congestion (cephalization, interstitial edema,
alveolar edema, pleural effusions) may be absent in spite of
a very high PCWP in patients with severe but chronic HF.
However, when present, it indicates a high PCWP.
xercise testing to assess functional classification might aid in assessment of residual congestion.
BNP  B-type natriuretic peptide; BP  blood pressure; BW  body weight; HF  heart failure;
VD  jugular venous distention; LV  left ventricle; LVDP  left ventricular diastolic pressure;No 
CAD
hat ma
b FlewT-proBNP  N-terminal pro-brain natriuretic peptide; PCWP  pulmonary capillary wedge
ressure; RA  right atrium.
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February 17, 2009:557–73 Acute HF Syndromesy high left-sided pressures (PCWP), may contribute to the
evelopment of the cardio-renal syndrome (56–59).
Body weight is often used as a marker of congestion in
oth inpatient and outpatient settings. However, recent data
uggest a more complex relationship among BW, conges-
ion, and outcomes. Although an increase in BW predicts
ospitalization (26,33), a reduction in BW in response to
ifferent therapies may not necessarily result in decreased
ospitalization or mortality. For example, vasopressin antago-
ists and non–potassium-sparing diuretics appear to decrease
W effectively, however, their use has not always been asso-
iated with an improvement in mortality or rehospitalization
60,61).
yocardial injury. Troponin release often occurs in
HFS, particularly in patients with CAD (14,62,63). This
ikely reflects myocardial injury, which may be related to
emodynamic and/or neurohormonal abnormalities or the
esult of an ischemic event (MI). Injury may also be the
onsequence of a high LV diastolic pressure, further acti-
ation of neurohormones, and/or inotropic stimulation,
esulting in a supply and demand mismatch (increased
yocardial oxygen demand and decreased coronary perfu-
ion) (38). These conditions may precipitate injury, partic-
larly in patients with CAD, who often have hibernating
nd/or ischemic myocardium (36). This is supported by
xperimental data in dogs where stimulation of hibernating
yocardium with low-dose dobutamine resulted in myocar-
Intrinsic Renal Disease
• Diabetes
• Hypertension
• Arteriosclerosis
Cardio-renal Sy
Worsening renal func
hospitalization, in spi
improvement in respo
therapy for HF and a
intravascular volume
Figure 2 The Cardio-Renal Syndrome
Both intrinsic/pre-existing structural kidney disease and potential contributors to r
from acute heart failure (HF) syndromes characterize the cardio-renal syndrome. Fiial necrosis (64). The importance of myocardial injury in bHFS has not been well studied and remains an area of
nvestigation.
enal impairment. In AHFS, renal abnormalities pro-
ote sodium and water retention (59). Structural renal
ysfunction due to diabetes, hypertension, and arterioscle-
osis, are common. Worsening renal function occurs in 20%
o 30% of patients during hospitalization (65,66). Recent
ata suggests that approximately 20% of patients have
orsening renal function soon after discharge (67). This
orsening during or after discharge may result from further
eurohormonal and hemodynamic abnormalities (low car-
iac output and/or high venous pressure), which may be
ggravated by high-dose loop diuretics (56–59,66,68) (Fig. 2).
enal dysfunction resulting from neurohormonal or hemo-
ynamic abnormalities (vasomotor nephropathy) may be
reventable or reversible and it is often referred as the
ardio-renal syndrome. In a given patient, distinguishing
etween vasomotor nephropathy from abnormalities related
o intrinsic kidney disease is often difficult and remains an
mportant area for research.
ntoward drug effects. Non–potassium-sparing intrave-
ous (IV) loop diuretics are first-line agents to alleviate
ongestive symptoms. However, those beneficial effects may
e associated with electrolyte abnormalities, further activa-
ion of neurohormones, and worsening renal function
68,69). High-dose administration of IV loop diuretics has
asomotor” Nephropathy
creased cardiac output and/or 
ystemic vasodilation
gh renal venous pressures
urohormonal activation
gh dose loop diuretic therapy
me
uring 
clinical
to 
ate 
jury
lustration by Rob Flewell.“V
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Acute HF Syndromes February 17, 2009:557–73owever, this association may be a marker of the severity of
F, rather than a cause of increased mortality (61,68,70).
Dobutamine, milrinone, and levosimendan improve he-
odynamics; however, these effects may be associated with
ncreased myocardial oxygen consumption (tachycardia and
ncreased contractility) and hypotension due to their vaso-
ilatory effects (71,72). Decreasing coronary perfusion due
o hypotension in the presence of increased myocardial
xygen demand may result in myocardial injury, particularly
n patients with CAD who often have ischemic or hiber-
ating myocardium (38).
Hypotension associated with the use of vasodilators may
lso result in myocardial and renal hypoperfusion and
ossibly injury (38,40–42,73).
rognostic Factors
ecent clinical trials and observational studies have identi-
ed emerging prognostic factors in patients admitted with
HFS (74–83) (Table 3).
P. Systolic BP on admission and early post-discharge is
merging as an important predictor of in-hospital and
ost-discharge mortality (21,33). It correlates inversely with
rognostic Indicators andote tial Targets f Therapy in AHFS*
Table 3 Prognostic Indicators andPotential Targets of Therapy in AHFS*
SBP Admission and early post-discharge SBP inversely
correlates with post-discharge mortality. The higher
the BP, the lower both in-hospital and post-
discharge mortality. However, the readmission rate
of approximately 30% is independent of the SBP at
time of admission (21).
CAD Extent and severity of CAD appears to be a predictor
of poor prognosis (36).
Troponin release Results in a 3-fold increase in in-hospital mortality, a
2-fold increase in post-discharge mortality, and a
3-fold increase in the rehospitalization rate (14,79).
Ventricular
dyssynchrony
Increase in QRS duration occurs in approximately 40%
of patients with reduced systolic function and is a
strong predictor of early and late post-discharge
mortality and rehospitalization (31).
Renal impairment Associated with a 2- to 3-fold increase in post-
discharge mortality. Worsening renal function
during hospitalization or soon after discharge is
also associated with an increase in in-hospital and
post-discharge mortality (33,66,70,80).
Hyponatremia Defined as serum sodium 135 mmol/l, occurs in
approximately 25% of patients, and is associated
with a 2- to 3-fold increase in post-discharge
mortality (30,94,95).
Clinical congestion at
time of discharge
An important predictor of post-discharge mortality and
morbidity (24,44).
EF Similar early post-discharge event rates and mortality
between reduced and preserved EF (6).
BNP/NT-proBNP Elevated natriuretic peptides associated with
increased resource utilization and mortality (81).
Functional capacity
at time of
discharge
Pre-discharge functional capacity, defined by the 6-
min walk test, is emerging as an important
predictor of post-discharge outcomes (82,83).
dapted and modified, with permission, from Gheorghiade et al. (5). *This is not an all-inclusive list.
CAD  coronary artery disease; other abbreviations as in Tables 1 and 2.ortality; high SBP at time of admission is associated with a hubstantially lower in-hospital and post-discharge mortality
21). However, the 60- to 90-day readmission rate remains
igh and appears independent of presenting BP (21).
AD. Patients with AHFS and CAD often have a worse
rognosis than other patients. This may be related to the
xtent and severity of CAD but also to the presence of other
omorbidities that are more common in these patients (36).
ibernating and/or ischemic myocardium is a therapeutic
arget for medical therapy and/or revascularization (36) (Fig.
). Unstable angina appears to be an important cause for
ospitalization in patients with chronic HF and PSF (84).
entricular dyssynchrony. A prolonged QRS complex, a
arker of ventricular dyssynchrony, is present in approximately
0% of patients with reduced systolic function hospitalized for
orsening HF. This is associated with an increase in early and
ate post-discharge mortality and hospitalization (31). Al-
hough chronic resynchronization therapy (CRT) appears to
e beneficial in patients with chronic HF and reduced systolic
unction with a prolonged QRS, this was not studied in AHFS
31,85). The prognostic value of QRS duration in patients with
HFS and PSF has not been studied.
rrhythmias. New sustained ventricular or atrial arrhyth-
ias developing during hospitalization are uncommon;
owever, when present, they predict an increase in post-
ischarge mortality (86).
enal impairment. Renal impairment is often present at
ime of admission (22). Approximately 30% of patients with
HFS have worsening renal function during hospitalization
87,88). Markers of renal impairment, either blood urea
itrogen, Cr, blood urea nitrogen/Cr ratio, estimated glo-
erular filtration rate, and/or cystatin C all have important
rognostic significance (22,66,87–93). Emerging data sug-
ests that an increase in blood urea nitrogen during the early
ost-discharge period is 1 of the most important predictors
f early mortality (33,67).
yponatremia. Mild hyponatremia occurs in 25% of pa-
ients with AHFS, irrespective of systolic function, and usually
emains uncorrected during hospitalization (30,94,95). These
yponatremic patients have the same hemodynamic and clin-
cal response as those with normonatremia, yet demonstrate a
ignificantly greater risk of death post-discharge (95). Al-
hough vasopressin antagonists (e.g., tolvaptan and conivaptan)
ffectively correct hyponatremia, their use has not been asso-
iated with improved outcomes (43,60,96).
ther prognostic factors. Troponin release, elevated na-
riuretic peptide levels, elevated PCWP, liver disease, ane-
ia, severe symptoms, older age, and increased heart rate
ppear to be markers of increased post-discharge mortality
isk (62,63,74,97–103). In contrast, the use of beta-
lockers, aldosterone antagonists, and ACE inhibitors is
ssociated with an improved prognosis (6). Recently, cardiac
atheterization has been associated with improvement in
ost-discharge outcomes. This improvement was related to
mplementation of evidence-based therapy for CAD during
ospitalization (105).
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February 17, 2009:557–73 Acute HF Syndromesvaluation Phases of AHFS Patients
our phases of hospital evaluation and management of
HFS are proposed: 1) initial or early phase (i.e., emer-
ency department); 2) in-hospital phase; 3) pre-discharge
hase; and 4) early post-discharge phase (5).
arly phase. This phase of AHFS management typically
akes place in the emergency department, where 80% of all
ospitalized patients initially present (15,16,18). Evaluation
nd management often proceeds concomitantly (Table 4).
fter stabilization/treatment of life-threatening conditions,
mproving hemodynamics and symptoms are key goals.
bnormal hemodynamics often results from conditions
uch as hypertension, ischemia, and/or arrhythmias. These
onditions, as well as any other precipitants of HF, should
e treated for optimal results.
The downstream impact of early therapy on outcomes for
HFS has not been well studied (106). Intravenous loop
iuretics with or without vasoactive agents (inotropes
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Figure 3 Assessment and Targeted Implementation of Evidence
Chart recommends assessment methods and ways to implement therapy. *Select
angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; AHA  American H
therapy; Dor procedure  ventricular reconstructive surgery to restore aneurysmal
able cardiac-defibrillator; ISDN  isosorbide dinitrate; LV  left ventricle; MAZE 
MRI  magnetic resonance imaging; other abbreviations as in Figure 1.nd/or vasodilators) improve symptoms in most patients a106 –109). The potential deleterious effects of these
herapies, if any, on the myocardium and kidney have not
een well studied (5). IV inotropes and vasodilators that
nitially improve signs and symptoms may adversely affect
ost-discharge outcomes (39,41,42,71,109,110). Deter-
ining if injury to key organs such as the heart or kidney
ccurs early or begins prior to presentation may shift the
herapeutic window upstream.
linical profiles at presentation. Initial management
hould be based on clinical profiles (Table 5). The presence
nd severity of underlying CAD may affect early manage-
ent decisions, because these patients may require addi-
ional therapies or may be adversely affected by other
herapies (e.g., inotropes) (39).
A universally accepted risk-stratification method appli-
able at the time of admission and a classification similar
o the Killip scoring system for acute MI is needed. In
eneral, risk stratification should consider baseline vari-
ods of Assessment
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ts; **investigational agents. ACC  American College of Cardiology; ACE-I 
sociation; ARB  angiotensin receptor blocker; CRT  chronic resynchronization
ntricle to its normal, elliptical shape; ECHO  echocardiography; ICD  implant-
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Acute HF Syndromes February 17, 2009:557–73arly post-discharge period. Severity of initial signs and
ymptoms may not always correlate with outcomes
33,76,77,102). Patients with severe signs of HF (pulmo-
ary edema) as a result of severe systemic hypertension
ay have better post-discharge outcomes than advanced
F patients with low EF who may present with less
evere symptoms (11).
nitial Management for AHFS*
Table 4 Initial Management for AHFS*
1. Treat immediate life-threatening
conditions/stabilize patient
Life-saving measures may precede
STEMI)
2. Establish the diagnosis Based on medical history, signs (JVD
3. Determine clinical profile and begin
initial treatment
Key components include HR, BP, JV
oximetry, history of CAD
4. Determine and manage the cause
or precipitant
Such as ischemia, hypertension, arr
and/or infectious etiologies is cri
5. Alleviate symptoms (e.g., dyspnea) Usually a diuretic with or without ot
6. Protect/preserve myocardium and
renal function
Avoid hypotension or increase in HR
low-output state (low BP with org
7. Make disposition Majority are admitted to telemetry,
disposition identifying the low-ris
These steps usually occur in parallel, not series. †Retrospective data suggests morphine is asso
CXR  chest X-ray; ECG  electrocardiogram; HR  heart rate; JVP  jugular venous pressure;
linical Profiles
Table 5 Clinical Profiles
Clinical Presentation Incidence*
Elevated BP (above 160 mm Hg) 25% Predominantly pulmona
systemic congestion.
Normal or moderately elevated BP 50% Develop gradually (days
systemic congestion.
may be minimal in pa
Low BP (90 mm Hg) 8% Mostly related to low car
decreased renal funct
Cardiogenic shock 1% Rapid onset. Primarily co
myocarditis, acute va
Flash pulmonary edema 3% Abrupt onset. Often prec
hypertension. Patient
and diuretics.
ACS and AHFS 25% of ACS have
HF signs/symptoms
Rapid or gradual onset.
symptoms of HF that
Isolated right HF from pulmonary
HTN or intrinsic RV failure (e.g.,
infarct) or valvular
abnormalities (e.g., tricuspid
valve endocarditis)
? Rapid or gradual onset d
hypertension or RV pa
characterized with litt
Post-cardiac surgery HF ? Occurring in patients wit
dysfunction, often rela
volume overload imm
subsequent early pos
by inadequate intra-o
in cardiac injury.
dapted and modified, with permission, from Gheorghiade et al. (5). *Of all AHFS admissions.
Represents initial therapies for early management and should be tailored to each patient’s uniqu
o the definition used (clinical versus radiographic). ¶Avoid if retaining CO2.
ACS  acute coronary syndromes; AHFS  acute heart failure syndromes; HTN  hypertension; IABP
ulmonary artery; RV  right ventricle; VAD  ventricular assist device.n-hospital phase. Further improvement of signs and
ymptoms, achieving euvolemia, and targeted initiation
nd/or up-titration of evidence-based therapies for chronic
F based on a comprehensive assessment are the goals of
his phase (11,13,48,111). Monitoring for potential car-
iac injury and renal function is important. The role
f serial B-type natriuretic peptide (BNP)/N-terminal
llel diagnostic evaluation (i.e., unstable arrhythmia, flash pulmonary edema,
dema), symptoms (dyspnea), biomarkers (e.g., BNP) and CXR
ence of pulmonary congestion, ECG, CXR, renal function, troponin, BNP, pulse
ias, acute valvular pathologies, worsening renal function, uncontrolled diabetes,
ensure maximal benefits from HF management
oactive agents. Morphine may also be used for pulmonary edema†
cularly in patients with CAD. Use of inotropes should be restricted to those with
operfusion)
small number discharged home. Robust evidence to support risk stratification and
nt for safe discharge with close outpatient follow-up is lacking
ith worse outcomes.
 ST-segment elevation myocardial infarction; other abbreviations as in Tables 1, 2, and 3.
teristics Targets† and Therapies‡
iographic/clinical) with or without
patients have preserved EF.
Target: BP and volume management
Therapy: vasodilators (e.g., nitrates§, nesiritide,
nitroprusside) and loop diuretics
ks) and are associated with
raphic pulmonary congestion
with advanced HF.
Target: volume management
Therapy: loop diuretics  vasodilators
utput and often associated with Target: cardiac output
Therapy: inotropes with vasodilatory properties
(e.g., milrinone, dobutamine, levosimendan);
consider digoxin (intravenous and/or orally)
 vasopressor medications  mechanical
assist devices (e.g., IABP)
ating acute MI, fulminant
isease.
Target: improve cardiac pump function
Therapy: inotropes  vasoactive medications 
mechanical assist devices, corrective surgery
d by severe systemic
nd readily to vasodilators
Target: BP, volume management
Therapy: vasodilators, diuretics, invasive or NIV,
morphine¶
uch patients may have signs and
e after resolution of ischemia.
Target: coronary thrombosis, plaque
stabilization, correction of ischemia
Therapy: reperfusion (e.g., PCI, lytics, nitrates,
antiplatelet agents)
primary or secondary PA
y (e.g., RV infarct). Not well
emiological data.
Target: PA pressure
Therapy: nitrates, epoprostenol,
phosphodiesterase inhibitors, endothelin-
blocking agents, coronary reperfusion for RV
infarcts, valve surgery
ithout previous ventricular
worsening diastolic function and
ly after surgery and the
tive interval. Can also be caused
e myocardial protection resulting
Target: volume management, improve cardiac
performance (output)
Therapy: diuretic or fluid administration
(directed by filling pressures and cardiac
index), inotropic support, mechanical
assistance (IABP, VAD)
ing etiology or precipitant is of equal of greater importance (e.g., arrhythmia, ACS, infection).
ntation. §Probably preferred in patients with ACS or history of CAD. Its incidence may be relatedor para
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February 17, 2009:557–73 Acute HF Syndromesro-BNP measurements in this setting remains to be
etermined.
Because dissociation between clinical (dyspnea, edema)
nd hemodynamic congestion (high LVFP) may be present
fter initial therapy, assessment of filling pressures is impor-
ant. Measurement of jugular venous pressure, if done
roperly, is an important bedside measurement of right
trial pressure (112,113). This is particularly important
ecause high right atrial pressure is a sign of elevated
eft-sided pressure. Orthostatic BP changes and the re-
ponse during Valsalva maneuver or sublingual nitroglycerin
ay aid in assessment of LVFP (24,113). Routine pulmo-
ary artery line-guided therapy in patients with severe HF
oes not result in improved outcomes (114). However, a
ulmonary artery line may be considered for refractory
igns and symptoms, particularly in the presence of
orsening renal function. The level of BNP/N-terminal
ro-BNP has also been proposed as a “measure” of
ongestion. A tailored approach with evidence-based
herapy in response to BNP levels in chronic HF was
ssociated with better outcomes in the outpatient setting
115). This approach remains to be investigated in
HFS. Currently, evidence and/or guidelines to assess
ongestion during hospitalization or pre-discharge are
ot well established.
Refractory or advanced HF should be managed according
o published guidelines (13,111,116). Thromboembolic
vents and myocardial ischemia should be considered in
atients not responding to standard therapy.
A thorough assessment to ensure implementation of
vidence-based guidelines (pharmacological, surgical, inter-
entional, and implantable cardiac-defibrillator/CRT)
hould occur during this phase or soon after discharge (Fig.
). The ADHERE (Acute Decompensated National Heart
ailure Registry) and OPTIMIZE-HF (Organized Pro-
ram to Initiate Life-Saving Treatment in Hospitalized
atients with Heart Failure) registries demonstrated the
elative paucity of comprehensive assessment (6,28). Hos-
italization presents opportunities to optimize manage-
ent, given the resources available in-hospital versus out-
atient. The traditional focus during hospitalization has
een on alleviating congestion (e.g., improving symptoms
nd decreased BW), rather than optimization of therapies
nown to improve outcomes in patients (37,117). Appro-
riate management of comorbidities (e.g., CAD, atrial
brillation, hypertension, diabetes mellitus) based on
vidence-based guidelines may also improve post-discharge
utcomes (35).
Of current HF quality measures (ACE inhibitor/
ngiotensin receptor blocker [ARB], anticoagulant at dis-
harge for HF patients with atrial fibrillation, assessment of
F, smoking cessation, and adequate discharge instruc-
ions), only ACE inhibitor/ARB has been shown to im-
rove outcomes in AHFS (8,118,119). It is doubtful that
hose measures alone will have a significant impact on
ost-discharge outcomes, given the complex pathophysiol- Hgy and heterogeneity of this patient population. Imple-
entation of evidence-based therapies (pharmacological,
lectrical devices, and surgical) based on comprehensive
ssessment may improve outcomes (13,120–125) (Fig. 3).
his important hypothesis remains to be tested.
re-discharge phase. Goals at discharge: 1) improve signs
nd symptoms; 2) appropriate management of precipitants;
) euvolemia with successful transition to oral diuretics;
) implementation or planned implementation of current
F guidelines; and 5) post-discharge planning and educa-
ion involving patients and family have been established,
ith clear instruction regarding weight monitoring, medi-
ations, and telephone and clinic follow-up. Formal assess-
ent of functional capacity (e.g., 6-min walk test) before
ischarge has not been well studied, and this may not be
easible or specific in many older patients.
Discharge criteria, which account for the heterogeneity of
he patient population and incorporate different strategies of
are, should be developed. Strategies for discharge after
omplete resolution of signs and symptoms compared with
arlier discharge with residual symptoms and close
ollow-up for further optimization should be studied.
arly post-discharge phase (“vulnerable” phase). Recent
ata demonstrates deterioration in signs and symptoms,
eurohormonal profile, and renal function during the first
ew weeks after discharge in patients who die or are
ehospitalized within 60 to 90 days (33). This deterioration
ccurs despite standard therapy, including beta-blockers,
CE inhibitors, or ARB, and often aldosterone-blocking
gents (33). Assessment of these variables in the early
ost-discharge period may provide unique opportunities to
urther optimize standard therapy (up-titration) and/or
ntroduce additional therapy known to improve outcomes
e.g., hydralazine/nitrates, aldosterone-blocking agents,
RT). In addition, the use of novel intravenous therapies
126,127) that are known to improve hemodynamics or to
reserve myocardial and renal function should be studied in
his vulnerable period.
ransitioning From Acute to Chronic HF
pproximately 80% of patients hospitalized with worsening
F have chronic HF. For the vast majority who stabilize
fter initial management, they should be considered as
hronic HF and be treated according to published guide-
ines (11,13,48,111,116,120,123–125,128–130).
Available data highlight gaps in utilization/optimization
f evidence-based therapies, such as beta-blockers, ACE
nhibitors, aldosterone-blocking agents, ARB, and electrical
evices (5,8,11,17,28,128,131). Recent analysis from the
WTG-HF (Get With the Guidelines–Heart Failure)
atabase showed variations by age, race, geographic region,
nd comorbidities on CRT uptake as well as differences
etween clinical trials and guideline recommendations
131). Initiation or up-titration of evidence-based chronicF therapies during hospitalization or soon after, absent
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ates (128).
arly Pharmacologic Management
harmacologic therapies have been reviewed extensively
lsewhere (126,127,132,133). Dyspnea, along with other
ymptoms and signs of AHFS, require urgent attention
pon presentation. In this setting, dyspnea is related to high
CWP. The increase of PCWP may be the result of
ifferent pathophysiological processes (e.g., hypertension,
schemia, arrhythmias, valvular disease), which often require
pecific therapies. Precipitants (e.g., dietary indiscretion,
neumonia, pulmonary embolism) may aggravate or worsen
he clinical profile and need to be taken into consideration
nd treated.
luid removal. Loop diuretics are the mainstay of therapy
n AHFS and effectively relieve symptoms. Continuous
nfusion has been recommended for improved efficacy and
or diuretic-resistant patients (11). Combination therapy
ith thiazide diuretics may also be considered (11,134). It is
rudent, however, not to rely totally on diuretics for fluid
emoval, as many patients are left with signs of HF despite
ymptomatic improvement. The addition of vasodilators
nd/or digoxin should be considered (46,135). The clinical
alue of new or emerging therapies for fluid removal, such as
ltrafiltration, vasopressin antagonists, and/or adenosine-
locking agents, remains to be determined.
In spite of their clinical benefits, non–potassium-sparing
iuretics may cause further neurohormonal and renal abnor-
alities (61,68). The potential negative effects of non–
otassium-sparing diuretics, as well as the optimal dose and
uration, however, have not been well studied and are currently
eing investigated in a large National Heart, Lung, and Blood
nstitutes trial (DOSE-AHF [Diuretic Optimal Strategy
valuation in Acute Heart Failure] study) (136).
Aldosterone-blocking agents may be particularly useful in
atients with AHFS, because the majority of patients have
vidence of right-sided failure, often resulting in liver
ongestion. This is often associated with increased serum
oncentrations of aldosterone despite standard therapies
e.g., ACE inhibitor) (33). Accordingly, both their neuro-
ormonal and diuretic effects (with higher doses) may be of
enefit. However, use of aldosterone-blocking agents in
HFS has not been studied.
LTRAFILTRATION. Ultrafiltration effectively removes fluid,
educes BW without improving dyspnea, and is associated
ith a decrease in readmission rates (137). These promising
esults need to be confirmed in a larger clinical trial.
ASOPRESSIN ANTAGONISTS. Tolvaptan, a vasopressin-2 an-
agonist, when added to standard therapy in patients admit-
ed with worsening chronic HF and reduced EF modestly
mproves hemodynamics, signs, and symptoms (e.g., BW,
yspnea) and normalizes serum sodium in hyponatremic
atients (43,107,138). Continuation of fixed doses of Aolvaptan after discharge decreased neither mortality nor
eadmission rates, in spite of a reduction in BW when
ompared with standard therapies (60,107). Conivaptan, a
asopressin-1 and -2 antagonist, has been approved by the
ood and Drug Administration only for treatment of
yponatremia. Although it has a similar hemodynamic
rofile when compared with tolvaptan, it does not improve
igns and symptoms in patients admitted with HF
138,139). The role of vasopressin antagonists in the man-
gement of AHFS remains to be determined.
DENOSINE ANTAGONISTS. Adenosine antagonists induce
iuresis via inhibition of sodium absorption in the proximal
ubule, block tubuloglomerular feedback, and therefore
reserve or increase glomerular filtration rate in HF
126,127,140–144). The PROTECT (Effects of Rolofyl-
ine, a New Adenosine A1 Receptor Antagonist, on Symp-
oms, Renal Function, and Outcomes in Patients With
cute Heart Failure) pilot trial suggested that rolofylline, a
elective A1 receptor antagonist, may improve symptoms
nd post-discharge outcomes, and is now being tested in a
arge outcome trial (145).
re-load and afterload reducers. NITROGLYCERIN. Nitro-
lycerin reduces LVFP, but its effects on clinical outcomes
ave not been well studied, although small studies suggest
enefit (106,146). It may be particularly useful in patients
ith AHFS and underlying CAD or acute coronary syn-
rome complicated by HF.
ITROPRUSSIDE. Nitroprusside is a powerful systemic vaso-
ilator, usually requires hemodynamic monitoring, and
ppears useful in patients with advanced HF (147). How-
ver, retrospective analysis demonstrated increased mortality
hen used early in patients with acute MI complicated by
evere HF, even when hemodynamics were monitored with
pulmonary artery catheter (40). The safety and efficacy of
itroprusside in AHFS has not been well studied.
ESIRITIDE. Nesiritide was approved for the treatment of
HFS in the U.S. in 2001, but not in Europe. It improves
emodynamics and dyspnea (109). Retrospective data raised
he hypothesis that it may worsen renal function and
ncrease post-discharge mortality (41,42). The safety and
fficacy of nesiritide is being tested in a large international
rial (ASCEND-HF [Double-Blind, Placebo-Controlled,
ulticenter Acute Study of Clinical Effectiveness of Ne-
iritide in Subjects With Decompensated Heart Failure]
rial) (148).
NTRAVENOUS ACE INHIBITORS. The American College of
mergency Physicians guidelines support the use of intra-
enous ACE inhibitors for initial AHFS therapy, although
s a Level C recommendation, while European Society of
ardiology guidelines do not support their use (11,48,149).
ntravenous enalaprilat may adversely affect outcomes when
sed early in patients with acute MI (73). The role of IV
CE inhibitors remains to be determined.
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February 17, 2009:557–73 Acute HF SyndromesELAXIN. Relaxin, an investigational vasodilator identical to
he native human neurohormone, appears in animal and
ilot clinical studies to be a potent vasodilator (150). It is
urrently being investigated in AHFS patients.
LARITIDE. Ularitide, a natriuretic peptide composed of 32
mino acid residues originally isolated from human urine,
as been evaluated in an early clinical trial (151,152). It
mproves hemodynamics and signs and symptoms, without
orsening renal function when compared with placebo
reatment. Severe hypotension, however, occurred at higher
oses (151,152).
notropes. Inotropes with vasodilatory properties, such as
obutamine, milrinone, and levosimendan (available in
urope) are known to improve hemodynamics (71,72,110).
hort-term use of IV milrinone without a bolus, when
dded to standard therapy, does not improve signs and
ymptoms, or reduce the total number of hospital days, and
as associated with severe hypotension and arrhythmias
71). In retrospect, it appeared to increase post-discharge
ortality in patients with CAD (39). These findings raised
he hypothesis that short-term administration of drugs may
ffect post-discharge outcomes, possibly by causing myocar-
ial injury due to decreased perfusion and/or increased
yocardial oxygen demand, particularly in patients with
AD who may have ischemic and/or hibernating myocar-
ium (38).
In AHFS, the short-term use of levosimendan improved
ymptoms and reduced the need for cointervention for
orsening HF; however, it was associated with significant
ide effects (hypotension, ventricular tachycardia) and a
rend toward increased early mortality (110). In patients
dmitted with very severe HF, levosimendan was not
uperior to dobutamine in terms of post-discharge mortality
hat was very high in both groups (72). In general, inotropes
ith vasodilator properties should be reserved for those
atients with a low output state, defined as low BP with sign
f organ hypoperfusion, who do not respond to other
herapies (13,111,116).
IGOXIN (IV). Digoxin improves hemodynamics in HF with-
ut activating neurohormones or negatively affecting heart rate,
P, or renal function (135,153,154). These effects are seen
hen used alone or in combination with other vasoactive
gents, including ACE inhibitors (135,153). Its chronic use
as been shown to decrease hospitalization when added to a
iuretic and ACE inhibitor (155). Although IV digoxin has all
he properties of an ideal agent in AHFS, its effects in AHFS
n patients with or without AF have not been studied (135).
STAROXIME. Istaroxime, an investigational inotrope with
usitropic properties, improves hemodynamics. In contrast
o current inotropes, it increases SBP and decreases heart
ate in AHFS (156). This agent appears promising for
atients presenting in a low-output state, manifested by a
ow BP (157). It is currently being tested in a larger clinical
rial. pARDIAC MYOSIN ACTIVATORS. Cardiac myosin activators, in
he early stages of clinical investigation, target myocardial
yosin adenosine triphosphatase, generating force to im-
rove contractility without changing intracellular concen-
rations of calcium (126,127). This molecule is currently
ndergoing further investigation in clinical trials (158,159).
ther therapies. A number of other treatments are com-
only given, although randomized clinical trial data are
acking. These therapies include morphine and oxygen
upplementation. The use of morphine in the ADHERE
egistry retrospectively points toward an association between
orphine and worse outcomes (160). Noninvasive ventila-
ion relieves dyspnea in AHFS (161). Although its use has
een associated with decreased resource utilization and
ortality, in the largest noninvasive ventilation trial to date,
o mortality benefit was seen over oxygen for either con-
inuous or bilevel noninvasive ventilation (161,162). How-
ver, this trial was not stratified by severity of presenting
llness (161). Adenosine-regulating agents are an emerging
herapy aimed to enhance endogenous adenosine-mediated
ardioprotective mechanisms (163). Soluble guanylate cy-
lase activators represent another emerging therapy; early
ata suggest beneficial arterial and venous vasodilatory
ffects (164). Direct renin inhibitors will be explored in
HFS in the ASTRONAUT (Aliskerin Trial on Acute
eart Failure Outcomes) trial.
linical Trials in AHFS
verall, clinical trial results have disappointed in terms of
fficacy and/or safety (41,42,60,71,72,107–109). In the last
5 years, only nesiritide has been approved for the treatment
f AHFS; however, post-approval questions of safety arose
41,42). These disappointing results may have been related to
he drug itself, failure to target the appropriate pathophysio-
ogic process, patient selection, and/or end points chosen. For
he majority of agents being studied in AHFS, gaps in our
nowledge exist (Table 6). In addition, demonstration of early
ymptomatic benefit beyond that of standard therapy alone is
ifficult given the significant beneficial response to available
herapies (107–109). A reassessment of how to conduct clinical
rials in AHFS is being investigated (5,165).
Dividing trials into stages has been proposed: Stage A is
arly intervention (i.e., emergency department); Stage B
nvolves in-hospital management; and Stage C is before or
oon after discharge (5).
Improving post-discharge outcomes is the most impor-
ant goal in AHFS; as such, future clinical trials should
ddress this issue. At the same time, both patients and
hysicians desire therapies that improve signs, symptoms,
nd/or quality of life, assuming an acceptable safety profile.
xpecting therapies used for 48 h to improve outcomes at 2
o 6 months in a complex, heterogeneous substrate such as
F may set the bar too high. This may negatively affect
esearch of therapies that may safely improve patient re-
orted outcomes (e.g., dyspnea). Another consideration
Therapies for AHFS
Table 6 Therapies for AHFS
Symptomatic
Improvement HR Hypotension LVFP Cardiac Output Arrhythmia
Coronary
Perfusion
Effect on
Viable But
Dysfunctional
Myocardium
Myocardial
Injury
(Tn)
Renal
Function
Neurohormonal
Activation
Effects on
Mortality
and/or
Rehospitalization
Fluid removal
Diuretics (IV) Yes Var Poss 2 Var ? ? ? ? ?2 Yes ?
K-sparing diuretics Poss N No ? ? No ? ? ? ? ? No 2*
Fluid removal—experimental
Vasopressin antagonists
(orally)
Yes N No 2 N No ? ? ? N ?† N
Adenosine antagonists (IV) ?1 N ? ? ? ? ? ? ? ?1 ? ?2
Vasodilators
Nitroglycerin (IV) Yes Var Poss 2 No No ?1 ? ? ? ?1 ?
Nitroprusside (IV) Yes Var Yes 2 Var No ?2 ? ? ? ? ?
Nesiritide (BNP) (IV) Yes Var Poss 2 No No ? ? ? ?2 ? ?1
Enalaprilat (IV) ? N Poss 2 No No ? ? ? ?2 2 ?
Vasodilators—experimental
Ularitide (urodilatin) Poss N Poss 2 ?1 ? ? ? ? ?N ? ?
Relaxin (IV) ? ? Poss 2 ? ? ? ? ? ? ? ?
Inotropes
Digoxin (IV) ? 2 No 2 1 No‡ ? ? ? N 2 2
Dopamine (IV) ? 1 No Dose dependent Dose dependent Dose dependent ? ? ? ? ? ?
Dobutamine (IV) ? Yes ?1 Poss 2 1 1 ? ?2 (may cause
injury)
Poss ? ? ?1
Levosimendan (IV) Yes 1 Poss 2 1 1 ? ? ? ? ? ?1
Enoximone Poss 1 Poss 2 1 1 ? ? ? ? ? ?
Milrinone (IV) N 1 Poss 2 1 1 ? ? ? ? ? ?1 in CAD
Inotropes—experimental
Cardiac myosin activators ? ? ? ? 1 ? ? ? ? ? ? ?
Istaroxime ? 2 No 2 1 May ? ? ? N No ?
Endothelin antagonists
Tezosentan N N Yes 2 1 No ? ? ? N ? N
Adapted and reproduced, with permission, from Shin et al. (127). *Aldosterone antagonists only. †Elevates vasopressin levels. ‡At proper therapeutic levels.
2  decrease;1  increase;N  no change or neutral; ?  unknown; IV  intravenous; K  potassium; LVFP  left ventricular filling pressure; May  may worsen or improve; Poss  possible; TN  troponin; Var  variable response; other abbreviations as in Tables
1 and 5.
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February 17, 2009:557–73 Acute HF Syndromesould be to create a novel end point, emphasizing the
mportance of bridging to evidence-based therapies. For
xample, in-hospital therapy with an investigational agent,
hich improves hemodynamics and symptoms, protects or
reserves the heart and/or kidneys, has a strong safety
rofile, and improves uptake of known life-saving therapies
e.g., ACE inhibitors, beta-blockers), might represent an
xcellent short-term goal. Subsequently, this may result in
mproved post-discharge outcomes.
A significant number of patients with early events have
orsening hemodynamics and neurohormonal and renal
bnormalities in the first few weeks after discharge. Accord-
ngly, early intervention during this vulnerable phase with
ntravenous (e.g., adenosine-blocking agents, guanylate cy-
lase activators, natriuretic peptides) or oral (e.g., vasopres-
in antagonists, renin inhibitors) and/or other therapeutic
nterventions (e.g., CRT, ultrafiltration) should be explored
n future clinical trials. Novel applications of existing ther-
pies (e.g., aldosterone-blocking agents, digoxin) should
lso be explored during this phase.
The present model of clinical development programs
ollows a stepwise progression, from in vitro to animal
odeling to first-in-human into clinical trials. Given the
till-limited understanding of the pathophysiology of AHFS, a
bidirectional” research approach may be in order. For exam-
le, during early clinical studies, new hypotheses may emerge;
n partnership with scientists, novel therapies would go back to
nimal models to try to answer these questions for both efficacy
nd safety, which would then lay the foundation for clinical
tudies.
onclusions
ospitalization for AHFS represents a significant and
rowing health care burden. Heterogeneity characterizes
his group in terms of mode of presentation, pathophysiol-
gy, and prognosis. The vast majority of patients symptom-
tically improve during hospitalization; however, their early
ost-discharge rehospitalization and mortality rates con-
inue to be extremely high. Worsening signs and symptoms
nd neurohormonal and renal abnormalities occurring soon
fter discharge may contribute to these high post-discharge
vent rates. Currently available assessment modalities com-
ined with recent advances in cardiovascular therapies
rovide present-day opportunities to improve post-
ischarge outcomes. Further investigation into pathophys-
ologic targets and novel approaches to clinical trial design
re needed. Improving post-discharge outcomes is the most
mportant goal in the management of AHFS.
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